By RNZ
Two new potential deals have emerged today – the small tree genetics company Arborgen, and the New Zealand investment and advisory operations of Australia's AMP.
The Australian newspaper speculated the New Zealand arm of AMP Capital is being …
VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.
